1. Characterization of anatomical variations of the nasal cavity in a subset of European patients and their impact on intranasal drug delivery.
- Author
-
Pasteur M, Arsouze G, Ilango G, Le Pennec D, Kulker D, Heyraud A, Cottier JP, Aussedat C, Heuzé-Vourc'h N, Hervé V, and Le Guellec S
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Tomography, X-Ray Computed, Europe, Nebulizers and Vaporizers, Fluorescein administration & dosage, Fluorescein pharmacokinetics, Nasal Sprays, Models, Anatomic, Aged, Drug Delivery Systems, Young Adult, Anatomic Variation, Administration, Intranasal, Nasal Cavity anatomy & histology, Printing, Three-Dimensional
- Abstract
Anatomical 3D-printed nasal casts are valuable models to investigate intranasal drug deposition, providing preclinical data that cannot be obtained in animal models. However, these models are limited since they are often derived from a single patient or represent a mean of several groups. The present study aimed to better characterize the anatomical differences of the nasal cavity in a European sub-population and to assess the potential impact of anatomical variations on intranasal deposition by medical devices. Ninety-eight cranial computed tomography scans of patients were selected and analyzed in 2D and 3D conformations. They showed symmetry of cavities and a high level of heterogeneity of measurements, especially volume and area, in the population. Three anatomical groups with distinct nasal geometry were identified and 3D nasal casts of the most representative patient of each group were printed. Fluorescein was administered using three medical devices: a nasal spray, a sonic jet nebulizer and a prototype mesh-nebulizer. The deposition profiles were compared with the Aeronose® as a reference. Our results show that anatomical variations influenced the deposition profiles depending on the device, with a higher variation with spray and the mesh-nebulizer. This work emphasises the importance of anatomical parameters on drug intranasal deposition and the need to evaluate inhaled drugs on different 3D nasal casts reflecting the target population., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: HERVE VIRGINIE reports financial support was provided by Research Center for Respiratory Diseases − Inserm U1100. LE GUELLEC SANDRINE reports a relationship with DTF medical that includes: employment. In the past 3 years, NHV and her group received research supports and subcontracting fees from medical device companies, including Aerogen and DTF medical outside the scope of the present study and from Aptar Pharma and Nemera on the development of nasal models. The Aeronose® model belong to equally to APTAR PHARMA/University of Tours – CEPR Inserm U1100/DTFmedical. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF